Results 41 to 50 of about 80,496 (306)
Human Vaccines & Immunotherapeutics, 2021 Hepatitis A virus (HAV) infections continue to represent a significant disease burden causing approximately 200 million infections, 30 million symptomatic illnesses and 30,000 deaths each year.
Christian Herzog +2 more
doaj +1 more source
, 2022 Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a ...
Aguiar, Jorge Agustin +5 more
core +1 more source
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source
Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. [PDF]
PLoS ONE, 2012 Although the use of recombinant hepatitis B virus surface (HBsAg) protein vaccine has successfully reduced global hepatitis B infection, there are still a number of vaccine recipients who do not develop detectable antibody responses.
Guohong Ge +5 more
doaj +1 more source
Hepatitis B virus infection in the Republic of Yemen [PDF]
A community-based cross-sectional household seroepdemiological survey was conducted in the Republic of Yemen to estimate the prevalence of HBV infection as well as hepatitis B vaccine coverage and effectiveness amongst children vaccinated in the ...
Qirbi, Naseeb
core +1 more source
Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro
Advanced Science, EarlyView.The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel +15 more
wiley +1 more source
Vaccination Strategies Against Hepatic Diseases: A Scoping Review
VaccinesBackground/Objectives: Viral hepatitis remains a significant global cause of chronic liver disease, highlighting the importance of effective vaccination strategies. This review assesses recent evidence on vaccine safety and effectiveness.
Zahra Beyzaei +3 more
doaj +1 more source
Advanced Science, EarlyView.This study reported renal‐clearable bio‐orthogonal near‐infrared fluorogenic probes (BGRs) that specifically imaging and urinalysis of granzyme B for dynamic evaluation of RCC immunotherapy. BGRs not only differentiate immunotherapeutic responses in orthotopic RCC mice, but also enable sensitive optical urinalysis of granzyme B in clinical specimens ...
Xingyue Yang +9 more
wiley +1 more source
VaccinesBackground: Co-administration of vaccines can impact the immune response and safety. We aim to systematically review the current scientific literature and find evidence regarding the immunogenicity and safety of pneumococcal vaccines co-administered with
Raziyeh Niyati +4 more
doaj +1 more source
Hepatitis A Vaccine Recommendations [PDF]
Pediatrics, 2007 This Policy Statement was retired July 2010. Since licensure in 1995 of a hepatitis A vaccine, the Centers for Disease Control and Prevention and the American Academy of Pediatrics have been implementing an incremental hepatitis A immunization strategy for children.
openaire +2 more sources